Independent fund research. Built on SEC filings.

How we research funds

ETF · Small-Cap · Oakmark (Harris)

Harbor Human Capital Factor US Small Cap ETF (HAPS)

Ticker HAPS · Since 2023-04-12 · · Holdings as of Jul 31, 2026

Expense ratio
0.61%$61/yr per $10k
1-yr return
+8.4%as of Dec 2025
Net assets
$170.6Mall share classes
Holdings
195

Bottom line

Is HAPS a good fund? The bottom line

HAPS is an actively managed small-cap ETF from Oakmark (Harris).

Annual fees run 0.61% — about $61 a year on every $10,000 invested, cheaper than 86% of small-cap funds we track.

It returned +8.4% over one year (as of Dec 31, 2025, per its prospectus).

With $171 million in net assets and 195 holdings, its largest position is Twist Bioscience Corp (2.9%) and the top 10 make up 18% of the portfolio.

What stands out

  • Low cost: cheaper than 86% of small-cap peers

Updated Nov 19, 2026

What HAPS invests in

The Fund seeks to provide investment results that correspond, before fees and expenses, to the performance of the Human Capital Factor Small Cap Index (the Index).

The Fund employs an indexing investment approach designed to track the performance of the Index. The Fund invests at least 80% of its total assets in securities that are included in the Index. The Index consists of a modified market capitalization-weighted portfolio of equity securities of approximately 200 small cap U.S. companies identified by Irrational Capital LLC (Irrational Capital or IC) as those it believes to possess strong corporate culture based on its proprietary scoring methodology. The Index was developed by the Canadian Imperial Bank of Commerce (the Index Provider or CIBC). Irrational Capital calculates Human Capital Factor scores based on a proprietary, rules-based scoring methodology it developed by leveraging its research in behavioral science, data science and human capital. The scoring methodology seeks to quantitatively measure the contribution of a companys…

From the fund's prospectus (filed Feb 27, 2026).

HAPS performance

Fund calendar-year total returns, 2024–2025 2024: +4.0%; 2025: +8.4% +4.0% 2024 +8.4% 2025
Fund gain (+)
Average annual total returns
1 yr5 yr10 yr
HAPS+8.4%——
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full HAPS performance history →

What HAPS costs

On a $10,000 investment, HAPS's 0.61% expense ratio costs about $61 a year. The prospectus estimates $762 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full HAPS fee table →

HAPS top 10 holdings

#Holding% of fund
1Twist Bioscience Corp2.86%
2Kymera Therapeutics Inc2.21%
3Phillips Edison & Co Inc1.97%
4Organon & Co1.71%
5Magnolia Oil & Gas Corp1.64%
6Sensient Technologies Corp1.62%
7Resideo Technologies Inc1.59%
8Avnet Inc1.59%
9Apple Hospitality REIT Inc1.49%
10Viasat Inc1.37%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 18% of the fund. See all top 25 holdings and asset mix →

Alternatives to HAPS

More funds like HAPS →

HAPS FAQ

What is the expense ratio of HAPS?
HAPS's expense ratio is 0.61%, which works out to about $61 a year for every $10,000 invested. The prospectus estimates total costs of $762 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is HAPS a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 86% of small-cap peers. This is general information, not personalized advice.
What does HAPS hold?
HAPS's largest holdings are Twist Bioscience Corp (2.9%), Kymera Therapeutics Inc (2.2%), Phillips Edison & Co Inc (2.0%), Organon & Co (1.7%), Magnolia Oil & Gas Corp (1.6%). It holds 195 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
Who manages HAPS?
HAPS is offered by Oakmark (Harris) through Harbor ETF Trust.